Kynurenate derivative attenuates the nitroglycerin-induced camKIIα and CGRP expression changes

Headache

Volumn 50, Issue 5, 2010, Pages 834-843

  Vámos, Eniko ^a   Fejes, Annamária ^a   Koch, Júlia ^a   Tajti, János ^a   Fülöp, Ferenc ^b   Toldi, József ^c   Párdutz, Árpád ^a   Vécsei, László ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

2 (2 N,N dimethylaminoethylamine 1 carbonyl) 1H quinolin 4 one hydrochloride; Calcitonin gene related peptide; Calmodulin dependent protein kinase II alpha; Caudal trigeminal nucleus; L kynurenine

Indexed keywords

2 (2 N,N DIMETHYLAMINOETHYLAMINE 1 CARBONYL) 1H QUINOLIN 4 ONE HYDROCHLORIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; EXCITATORY AMINO ACID RECEPTOR; GLYCERYL TRINITRATE; KYNURENIC ACID DERIVATIVE; KYNURENINE; PROBENECID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MIGRAINE; NEUROMODULATION; NEUROPIL; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRIGEMINAL NUCLEUS; UPREGULATION;

ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; GENE EXPRESSION REGULATION, ENZYMOLOGIC; ISOENZYMES; KYNURENIC ACID; KYNURENINE; MALE; NITROGLYCERIN; RATS; RATS, SPRAGUE-DAWLEY; TRIGEMINAL CAUDAL NUCLEUS;

EID: 77951836040     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2009.01574.x     Document Type: Article

References (52)

1. Sicuteri F, Del BE, Poggioni M, Bonazzi A. Unmasking latent dysnociception in healthy subjects. Headache. 1987 27 : 180 185. (Pubitemid 18001961)
2. Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: A possible molecular mechanism of migraine pain. Neuroreport. 1993 4 : 1027 1030. (Pubitemid 23242637)
3. Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain. 2004 110 : 675 680. (Pubitemid 39036799)
4. Olesen J, Thomsen LL, Lassen LH, Olesen IJ. The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia. 1995 15 : 94 100. (Pubitemid 24156497)
5. Tassorelli C, Joseph SA. Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Res. 1995 682 : 167 181.
6. Pardutz A, Krizbai I, Multon S, Vecsei L, Schoenen J. Systemic nitroglycerin increases nNOS levels in rat trigeminal nucleus caudalis. Neuroreport. 2000 11 : 3071 3075.
7. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000 123 Pt 8 1703 1709. (Pubitemid 30481193)
8. Pardutz A, Hoyk Z, Varga H, Vecsei L, Schoenen J. Oestrogen-modulated increase of calmodulin-dependent protein kinase II (CamKII) in rat spinal trigeminal nucleus after systemic nitroglycerin. Cephalalgia. 2007 27 : 46 53. (Pubitemid 46020801)
9. Hudmon A, Schulman H. Structure-function of the multifunctional Ca2+/calmodulin-dependent protein kinase II. Biochem J. 2002 364 : 593 611. (Pubitemid 34680833)
10. Pardutz A, Multon S, Malgrange B, Parducz A, Vecsei L, Schoenen J. Effect of systemic nitroglycerin on CGRP and 5-HT afferents to rat caudal spinal trigeminal nucleus and its modulation by estrogen. Eur J Neurosci. 2002 15 : 1803 1809. (Pubitemid 35471905)
11. Arulmani U, Maassenvandenbrink A, Villalon CM, Saxena PR. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol. 2004 500 : 315 330. (Pubitemid 39304018)
12. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990 28 : 183 187. (Pubitemid 20244522)
13. Durham PL. CGRP receptor antagonists: A new choice for acute treatment of migraine? Curr Opin Investig Drugs. 2004 5 : 731 735.
14. Andreou AP, Goadsby PJ. Therapeutic potential of novel glutamate receptor antagonists in migraine. Expert Opin Investig Drugs. 2009 18 : 789 803.
15. Oshinsky ML, Luo J. Neurochemistry of trigeminal activation in an animal model of migraine. Headache. 2006 46 (Suppl. 1 S39 S44. (Pubitemid 43794788)
16. Ferrari A, Spaccapelo L, Pinetti D, Tacchi R, Bertolini A. Effective prophylactic treatments of migraine lower plasma glutamate levels. Cephalalgia. 2009 29 : 423 429.
17. Sang CN, Ramadan NM, Wallihan RG, et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia. 2004 24 : 596 602.
18. Tallaksen-Greene SJ, Young AB, Penney JB, Beitz AJ. Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the rat. Neurosci Lett. 1992 141 : 79 83.
19. Kessler M, Terramani T, Lynch G, Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: Characterization and identification of a new class of antagonists. J Neurochem. 1989 52 : 1319 1328. (Pubitemid 19085960)
20. Knyihar-Csillik E, Toldi J, Krisztin-Peva B, et al. Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid. Neurosci Lett. 2007 418 : 122 126. (Pubitemid 46635993)
21. Kiss C, Shepard PD, Bari F, Schwarcz R. Cortical spreading depression augments kynurenate levels and reduces malonate toxicity in the rat cortex. Brain Res. 2004 1002 : 129 135. (Pubitemid 38251586)
22. Cunningham RF, Israili ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet. 1981 6 : 135 151.
23. Vecsei L, Miller J, MacGarvey U, Beal MF. Effects of kynurenine and probenecid on plasma and brain tissue concentrations of kynurenic acid. Neurodegeneration. 1992 1 : 17 26.
24. Vamos E, Pardutz A, Varga H, et al. l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus. Neuropharmacology. 2009 doi:10.1016/j.neuropharm.2009.06.033.
25. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: Implications for brain synthesis and metabolism. J Neurochem. 1991 56 : 2007 2017.
26. Santamaria A, Rios C, Solis-Hernandez F, et al. Systemic DL-kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats. Neuropharmacology. 1996 35 : 23 28. (Pubitemid 26064940)
27. Knyihar-Csillik E, Mihaly A, Krisztin-Peva B, et al. The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: Comparative studies of the effects of SZR-72 and kynurenic acid. Neurosci Res. 2008 61 : 429 432.
28. Liang DY, Li X, Clark JD. Formalin-induced spinal cord calcium/calmodulin-dependent protein kinase II alpha expression is modulated by heme oxygenase in mice. Neurosci Lett. 2004 360 : 61 64. (Pubitemid 38471988)
29. Fang L, Wu J, Lin Q, Willis WD. Calcium-calmodulin-dependent protein kinase II contributes to spinal cord central sensitization. J Neurosci. 2002 22 : 4196 4204. (Pubitemid 37465726)
30. Ogawa A, Dai Y, Yamanaka H, Iwata K, Niwa H, Noguchi K. Ca(2+)/calmodulin-protein kinase IIalpha in the trigeminal subnucleus caudalis contributes to neuropathic pain following inferior alveolar nerve transection. Exp Neurol. 2005 192 : 310 319. (Pubitemid 40341677)
31. Kolaj M, Cerne R, Cheng G, Brickey DA, Randic M. Alpha subunit of calcium/calmodulin-dependent protein kinase enhances excitatory amino acid and synaptic responses of rat spinal dorsal horn neurons. J Neurophysiol. 1994 72 : 2525 2531. (Pubitemid 24362643)
32. Sluka KA, Dougherty PM, Sorkin LS, Willis WD, Westlund KN. Neural changes in acute arthritis in monkeys. III. Changes in substance P, calcitonin gene-related peptide and glutamate in the dorsal horn of the spinal cord. Brain Res Brain Res Rev. 1992 17 : 29 38.
33. Garry MG, Walton LP, Davis MA. Capsaicin-evoked release of immunoreactive calcitonin gene-related peptide from the spinal cord is mediated by nitric oxide but not by cyclic GMP. Brain Res. 2000 861 : 208 219.
34. Zhang RX, Mi ZP, Qiao JT. Changes of spinal substance P, calcitonin gene-related peptide, somatostatin, Met-enkephalin and neurotensin in rats in response to formalin-induced pain. Regul Pept. 1994 51 : 25 32.
35. Vikelis M, Mitsikostas DD. The role of glutamate and its receptors in migraine. CNS Neurol Disord Drug Targets. 2007 6 : 251 257. (Pubitemid 47232936)
36. Hill RG, Salt TE. An ionophoretic study of the responses of rat caudal trigeminal nucleus neurones to non-noxious mechanical sensory stimuli. J Physiol. 1982 327 : 65 78.
37. Bereiter DA, Benetti AP. Excitatory amino release within spinal trigeminal nucleus after mustard oil injection into the temporomandibular joint region of the rat. Pain. 1996 67 : 451 459.
38. Goadsby PJ, Classey JD. Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. Brain Res. 2000 875 : 119 124.
39. Haley JE, Sullivan AF, Dickenson AH. Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat. Brain Res. 1990 518 : 218 226. (Pubitemid 20197052)
40. Davies SN, Lodge D. Evidence for involvement of N-methylaspartate receptors in "wind-up" of class 2 neurones in the dorsal horn of the rat. Brain Res. 1987 424 : 402 406. (Pubitemid 18047687)
41. Mitsikostas DD, Sanchez del RM, Waeber C, Moskowitz MA, Cutrer FM. The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain. 1998 76 : 239 248. (Pubitemid 28304962)
42. Liu S, Ruenes GL, Yezierski RP. NMDA and non-NMDA receptor antagonists protect against excitotoxic injury in the rat spinal cord. Brain Res. 1997 756 : 160 167. (Pubitemid 27241621)
43. Woolf CJ. Pain. Neurobiol Dis. 2000 7 : 504 510.
44. Hardingham GE, Bading H. The Yin and Yang of NMDA receptor signalling. Trends Neurosci. 2003 26 : 81 89. (Pubitemid 36110542)
45. Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 2001 313 : 96 98. (Pubitemid 32973903)
46. Storer RJ, Goadsby PJ. Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors. Neuroscience. 1999 90 : 1371 1376. (Pubitemid 29170152)
47. Perkins MN, Stone TW. Actions of kynurenic acid and quinolinic acid in the rat hippocampus in vivo. Exp Neurol. 1985 88 : 570 579.
48. Prescott C, Weeks AM, Staley KJ, Partin KM. Kynurenic acid has a dual action on AMPA receptor responses. Neurosci Lett. 2006 402 : 108 112. (Pubitemid 43766458)
49. Rozsa E, Robotka H, Vecsei L, Toldi J. The Janus-face kynurenic acid. J Neural Transm. 2008 115 : 1087 1091.
50. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: Physiopathological implications. J Neurosci. 2001 21 : 7463 7473. (Pubitemid 32904945)
51. * nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J Neurochem. 2002 80 : 1071 1078. (Pubitemid 34809959)
52. Roffey P, Mikhail M, Thangathurai D. NMDA receptor blockade prevents nitroglycerin-induced headaches. Headache. 2001 41 : 733. (Pubitemid 32777760)